Literature DB >> 27167129

Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Aubin Moutal1, Erik T Dustrude1, Rajesh Khanna2,3.   

Abstract

Neurofibromatosis type 1 (Nf1) is a progressive, autosomal disorder with a large degree of variability and severity of manifestations including neurological, cutaneous, ocular/orbital, orthopedic, and vascular abnormalities. Nearly half of Nf1 patients presents with cognitive impairment, specifically spatial learning deficits. These clinical manifestations suggest a global impairment of both central and peripheral nervous system functions in neurofibromatosis. Nf1 encodes for neurofibromin, a Ras GTPase-activating protein (Ras GAP) that has been implicated in the regulation of long-term potentiation (LTP), Ras/ERK (extracellular signal-regulated kinase) signaling, and learning in mice. Over the last decades, mice with a targeted mutation in the Nf1 gene, Nf1 -/- chimeric mice, Nf1 exon-specific knockout mice, and mice with tissue-specific inactivation of Nf1 have been generated to model the human Nf1 disease. These studies have implicated neurofibromin in regulation of the release of the inhibitory neurotransmitter γ-amino butyric acid (GABA) in the hippocampus and frontal lobe, which can regulate memory. Mutations in neurofibromin thus lead to perturbed ERK signaling, which alters GABA release, LTP, and subsequently leads to learning deficits. In addition to these cognitive deficits, Nf1 patients also have defects in fine and gross motor coordination as well as decreased muscle strength. Although the mechanisms underlying these motor deficits are unknown, deficits in GABAergic neurotransmission in both the motor cortex and cerebellum have been suggested. In this review, we present evidence to support the hypothesis that alterations of ion channel activity in Nf1 underscore the dysregulated neuronal communication in non-neuronal and neuronal cells that likely contributes to the clinical cornucopia of Nf1.

Entities:  

Keywords:  GABA receptors; Hyperpolarization-activated cyclic nucleotide-gated channel; Neurofibromin; Small conductance calcium-activated potassium channels; Voltage-gated calcium channels; Voltage-gated sodium channels

Mesh:

Substances:

Year:  2016        PMID: 27167129     DOI: 10.1007/s12035-016-9907-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  60 in total

1.  Neurofibromin regulates HCN activity in Parvalbumin-positive interneurons.

Authors:  A Omrani; G M van Woerden; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-11       Impact factor: 15.992

2.  Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism.

Authors:  Yanfang Xu; Nipavan Chiamvimonvat; Ana E Vázquez; Shailaja Akunuru; Nancy Ratner; Ebenezer N Yamoah
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

Review 3.  Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.

Authors:  Rui M Costa; Alcino J Silva
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

4.  N-type calcium current, Cav2.2, is enhanced in small-diameter sensory neurons isolated from Nf1+/- mice.

Authors:  J-H Duan; K E Hodgdon; C M Hingtgen; G D Nicol
Journal:  Neuroscience       Date:  2014-04-19       Impact factor: 3.590

5.  Impaired long-term memory and long-term potentiation in N-type Ca2+ channel-deficient mice.

Authors:  D Jeon; C Kim; Y-M Yang; H Rhim; E Yim; U Oh; H-S Shin
Journal:  Genes Brain Behav       Date:  2006-08-29       Impact factor: 3.449

6.  Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line.

Authors:  Eriko Fujimoto; Hiromi Sato; Sumiko Shirai; Yoji Nagashima; Keiko Fukumoto; Hiromi Hagiwara; Etsuko Negishi; Koichi Ueno; Yasufumi Omori; Hiroshi Yamasaki; Kiyokazu Hagiwara; Tomohiro Yano
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 9.867

7.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

8.  New function for NF1 tumor suppressor.

Authors:  J Koivunen; H Ylä-Outinen; T Korkiamäki; S L Karvonen; M Pöyhönen; M Laato; J Karvonen; S Peltonen; J Peltonen
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

9.  Altered calcium-mediated cell signaling in keratinocytes cultured from patients with neurofibromatosis type 1.

Authors:  Timo Korkiamäki; Heli Ylä-Outinen; Jussi Koivunen; Seija-Liisa Karvonen; Juha Peltonen
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

10.  Connexin 32 dysfunction promotes ethanol-related hepatocarcinogenesis via activation of Dusp1-Erk axis.

Authors:  Hiroyuki Kato; Aya Naiki-Ito; Taku Naiki; Shugo Suzuki; Yoriko Yamashita; Shinya Sato; Hiroyuki Sagawa; Akihisa Kato; Toshiya Kuno; Satoru Takahashi
Journal:  Oncotarget       Date:  2016-01-12
View more
  8 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  CRMP2-Neurofibromin Interface Drives NF1-related Pain.

Authors:  Aubin Moutal; Li Sun; Xiaofang Yang; Wennan Li; Song Cai; Shizhen Luo; Rajesh Khanna
Journal:  Neuroscience       Date:  2018-04-12       Impact factor: 3.590

Review 3.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

4.  CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Authors:  Aubin Moutal; Xiaofang Yang; Wennan Li; Kerry B Gilbraith; Shizhen Luo; Song Cai; Liberty François-Moutal; Lindsey A Chew; Seul Ki Yeon; Shreya S Bellampalli; Chaoling Qu; Jennifer Y Xie; Mohab M Ibrahim; May Khanna; Ki Duk Park; Frank Porreca; Rajesh Khanna
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

5.  A porcine model of neurofibromatosis type 1 that mimics the human disease.

Authors:  Katherine A White; Vicki J Swier; Jacob T Cain; Jordan L Kohlmeyer; David K Meyerholz; Munir R Tanas; Johanna Uthoff; Emily Hammond; Hua Li; Frank A Rohret; Adam Goeken; Chun-Hung Chan; Mariah R Leidinger; Shaikamjad Umesalma; Margaret R Wallace; Rebecca D Dodd; Karin Panzer; Amy H Tang; Benjamin W Darbro; Aubin Moutal; Song Cai; Wennan Li; Shreya S Bellampalli; Rajesh Khanna; Christopher S Rogers; Jessica C Sieren; Dawn E Quelle; Jill M Weimer
Journal:  JCI Insight       Date:  2018-06-21

Review 6.  Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.

Authors:  Carl E Stafstrom; Verena Staedtke; Anne M Comi
Journal:  Front Neurol       Date:  2017-03-17       Impact factor: 4.003

7.  CRMP2 is necessary for Neurofibromatosis type 1 related pain.

Authors:  Aubin Moutal; Song Cai; Shizhen Luo; Raphaëlle Voisin; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2018-01-01       Impact factor: 2.581

8.  CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain.

Authors:  Lindsey A Chew; Rajesh Khanna
Journal:  Neuronal Signal       Date:  2018-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.